ESMO 2021 | Safety and efficacy of SKB264 for the treatment of advanced or metastatic solid tumors
Elena Garralda, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, describes the preliminary results from a Phase I study investigating the safety and efficacy of a novel anti-TROP2 antibody-drug conjugate (ADC), SKB264, for the treatment of advanced or metastatic solid tumours. Findings from this study demonstrated that SKB264 is well-tolerated and has a similar safety profile in comparison to other anti-TROP2 ADCs. The response rate (RR) was 35.3% and the disease control rate (DCR) reached 70.6%. In addition, the drug showed efficacy in patients that did not respond to sacituzumab govitecan, an approved anti-TROP2 ADC. Dr Garralda explains that in addition to releasing a different payload, SKB264 is conjugated to a linker that is more stable than the linker conjugated to sacituzumab govitecan. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
